Get notified when VOR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVor Biopharma appoints Dr. David Zaccardelli to Board following director resignation
Filed July 7, 2026 · Period ending July 6, 2026 · ~1 min read
Key Changes
-
medium
Dr. David Zaccardelli appointed as independent Class II director, bringing experience as former CEO of Verona Pharma (acquired by Merck 2025) and Dova Pharmaceuticals (acquired by Sobi 2019).
Item 5.02 verify on EDGAR → -
low
Dr. Andrew Levin resigned from the Board effective July 6, 2026, with the filing stating the resignation was not due to any disagreement with the Company.
Item 5.02 verify on EDGAR → -
low
Dr. Zaccardelli will receive standard non-employee director compensation: $40,000 annual cash retainer and initial stock options for up to 68,000 shares or $700,000 fair value.
Item 5.02 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FDS 10-Q) is open in full — no account needed.
Partner
Trade VOR commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jul 7, 2026 · How we verify